Obesity and weight health articles covering diabetes risk, GLP-1 medicines, lifestyle support, metabolic health, stigma, and long-term care questions.Weight is influenced by biology, environment, medicines, sleep, stress, and access to care. Effective support should be respectful, evidence-aware, and individualized.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
Retatrutide: A New Horizon in Diabetes and Obesity Management: evidence-based guidance reviewed against current NICE and ADA recommendations. Practical.
Managing GLP-1 Side Effects: A Practical Guide: practical strategies for managing common side effects, when to call your team, and how to stay on track.
What to Expect in Your First Month on Semaglutide: how it works, who it’s used for, common side effects, and current NICE NG28 guidance. Evidence-based guide.
